Pluristem Therapeutics, Inc. (PSTI) financial statements (2021 and earlier)

Company profile

Business Address MATAM ADVANCED TECHNOLOGY PARK
HAIFA, 3508409
State of Incorp. NV
Fiscal Year End June 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
3/31/2020
Q3
12/31/2019
Q2
9/30/2019
Q1
6/30/2019
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:46535916172025
Cash and cash equivalents8787744
Short-term investments353438891520
Other undisclosed cash, cash equivalents, and short-term investments313131111
Restricted cash and investments011111 
Receivables  0   0
Other current assets2222322
Other undisclosed current assets(3)(13)(13)(1)(1)(1)(1)
Total current assets:45434818192126
Noncurrent Assets
Operating lease, right-of-use asset111112 
Property, plant and equipment2233334
Long-term investments and receivables312130000
Long-term investments312130000
Other noncurrent assets0000000
Other undisclosed noncurrent assets1111111
Total noncurrent assets:716175665
TOTAL ASSETS:52596623252831
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7554457
Accounts payable3222232
Accrued liabilities4433324
Employee-related liabilities  0   0
Deferred revenue  0    
Debt   111 
Other undisclosed current liabilities3322222
Total current liabilities:10887788
Noncurrent Liabilities
Long-term debt and lease obligation001111 
Operating lease, liability001111 
Liabilities, other than long-term debt1111111
Liability, pension and other postretirement and postemployment benefits1111111
Other liabilities 0    0
Total noncurrent liabilities:1212221
Total liabilities:1110999109
Stockholders' equity
Stockholders' equity attributable to parent, including:41495614161822
Common stock      0
Additional paid in capital342338336286280276273
Accumulated deficit(301)(289)(280)(272)(265)(258)(251)
Stockholders' equity note, subscriptions receivable(41)(49)(56)(14)(16)(18)(22)
Other undisclosed stockholders' equity attributable to parent41495614161822
Total stockholders' equity:41495614161822
TOTAL LIABILITIES AND EQUITY:52596623252831

Income statement (P&L) ($ in millions)

12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
3/31/2020
Q3
12/31/2019
Q2
9/30/2019
Q1
6/30/2019
Q4
Revenues   000 
Sublease income   0 0 
Cost of revenue    (0)  
Other undisclosed gross profit  0    
Gross profit:  0000 
Operating expenses(13)(9)(9)(7)(7)(8)(9)
Other undisclosed operating income0000101
Operating loss:(13)(9)(9)(7)(6)(7)(8)
Nonoperating income (expense)  0(0)(0)00
Net loss:(13)(9)(8)(8)(6)(7)(8)
Other undisclosed net income attributable to parent10     
Net loss available to common stockholders, diluted:(13)(8)(8)(8)(6)(7)(8)

Comprehensive Income ($ in millions)

12/31/2020
Q2
9/30/2020
Q1
6/30/2020
Q4
3/31/2020
Q3
12/31/2019
Q2
9/30/2019
Q1
6/30/2019
Q4
Net loss:(13)(9)(8)(8)(6)(7)(8)
Comprehensive loss, net of tax, attributable to parent:(13)(9)(8)(8)(6)(7)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: